📊 OPRX Key Takeaways
Is OptimizeRx Corp (OPRX) a Good Investment?
OptimizeRx exhibits strong operational efficiency with 67.3% gross margins and robust 17% free cash flow margins, supported by a conservative balance sheet and excellent liquidity. However, flat revenue growth (0% YoY), very low returns on equity (4.0%) and assets (2.9%), and inefficient capital deployment significantly limit upside potential.
Why Buy OptimizeRx Corp Stock? OPRX Key Strengths
- Exceptional gross margin of 67.3% with strong free cash flow generation (17% FCF margin)
- Conservative balance sheet with low debt/equity (0.20x) and excellent liquidity (3.04x current ratio)
- Consistent profitability with positive operating cash flow of $18.7M despite minimal capex requirements
OPRX Stock Risks: OptimizeRx Corp Investment Risks
- Zero revenue growth (0% YoY) indicates complete business stagnation with no organic growth momentum
- Very low capital returns (4% ROE, 2.9% ROA) despite strong margins suggest severe capital inefficiency
- Wide margin compression from 10.7% operating margin to 4.7% net margin signals high overhead or non-operating expenses
Key Metrics to Watch
- Revenue growth rate and new customer acquisition trends
- Return on equity improvement and capital deployment strategy
- Operating expense ratio and SG&A efficiency
OptimizeRx Corp (OPRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.04x current ratio provides a solid financial cushion.
OPRX Profit Margin, ROE & Profitability Analysis
OPRX vs Services Sector: How OptimizeRx Corp Compares
How OptimizeRx Corp compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is OptimizeRx Corp Stock Overvalued? OPRX Valuation Analysis 2026
Based on fundamental analysis, OptimizeRx Corp has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
OptimizeRx Corp Balance Sheet: OPRX Debt, Cash & Liquidity
OPRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: OptimizeRx Corp's revenue has grown significantly by 2,323% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.10 indicates the company is currently unprofitable.
OPRX Revenue Growth, EPS Growth & YoY Performance
OPRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $21.3M | $112.0K | $0.01 |
| Q2 2025 | $18.8M | -$667.0K | $-0.04 |
| Q1 2025 | $19.7M | -$2.2M | $-0.12 |
| Q3 2024 | $16.3M | -$2.9M | $-0.17 |
| Q2 2024 | $13.8M | -$4.0M | $-0.22 |
| Q1 2024 | $13.0M | -$6.4M | $-0.37 |
| Q3 2023 | $15.1M | -$2.9M | $-0.17 |
| Q2 2023 | $13.8M | -$3.8M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
OptimizeRx Corp Dividends, Buybacks & Capital Allocation
OPRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for OptimizeRx Corp (CIK: 0001448431)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OPRX
What is the AI rating for OPRX?
OptimizeRx Corp (OPRX) has an AI rating of HOLD with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are OPRX's key strengths?
Claude: Exceptional gross margin of 67.3% with strong free cash flow generation (17% FCF margin). Conservative balance sheet with low debt/equity (0.20x) and excellent liquidity (3.04x current ratio).
What are the risks of investing in OPRX?
Claude: Zero revenue growth (0% YoY) indicates complete business stagnation with no organic growth momentum. Very low capital returns (4% ROE, 2.9% ROA) despite strong margins suggest severe capital inefficiency.
What is OPRX's revenue and growth?
OptimizeRx Corp reported revenue of $109.4M.
Does OPRX pay dividends?
OptimizeRx Corp does not currently pay dividends.
Where can I find OPRX SEC filings?
Official SEC filings for OptimizeRx Corp (CIK: 0001448431) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OPRX's EPS?
OptimizeRx Corp has a diluted EPS of $0.27.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OPRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, OptimizeRx Corp has a HOLD rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OPRX stock overvalued or undervalued?
Valuation metrics for OPRX: ROE of 4.0% (sector avg: 16%), net margin of 4.7% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy OPRX stock in 2026?
Our dual AI analysis gives OptimizeRx Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OPRX's free cash flow?
OptimizeRx Corp's operating cash flow is $18.7M, with capital expenditures of $58.0K. FCF margin is 17.0%.
How does OPRX compare to other Services stocks?
Vs Services sector averages: Net margin 4.7% (avg: 10%), ROE 4.0% (avg: 16%), current ratio 3.04 (avg: 1.5).